inderal 10 mg migraine bupropion tablets images dutasteride
buy windows 7 professional family pack buy indesign cs6 from adobe discount parallels desktop 10 for mac
best price adobe flash professional cc 2014 autocad lt 2014 price cs6 production premium price mac
viagra pas cher en ligne medicamento levitra viagra basso prezzo
viagra 100mg preis acheter viagra acheter cialis pas cher
  • cialis in farmacia senza ricetta avis site de vente viagra viagra senza ricetta in svizzera
  • viagra alternatives australia how to get viagra australia australia over the counter viagra
    canadian pharmacies for celebrex medicine can you buy nolvadex over the counter tretinoin cream price in india

    Germany’s Merck halts supply of cancer drug to Greek hospitals

    Mon, Nov 5, 2012

    Oral Cancer News


    Date: November 3, 2012

    German pharmaceuticals firm Merck KGaA is no longer delivering cancer drug Erbitux to Greek hospitals, a spokesman said on Saturday, the latest sign of how an economic and budget crisis is hurting frontline public services.

    Drugmakers raised concerns with EU leaders earlier this year over supplies to the euro zone’s crisis-hit southern half and Germany’s Biotest in June was the first to stop shipments to Greece because of unpaid bills.

    Publicly-owned hospitals in some countries worst hit by the euro zone debt crisis had been struggling to pay their bills, Merck’s chief financial officer, Matthias Zachert, was quoted as saying by German paper Boersen-Zeitung in an interview on Saturday.

    He said however that the only country where Merck had stopped deliveries was Greece.

    “It only affects Greece, where we have been faced with many problems. It’s just the one product,” he told the paper.

    A spokesman for the company told Reuters that the drug concerned was Erbitux and that ordinary Greeks can still purchase it from pharmacies.

    Some countries have taken action to pay bills, such as in Spain, where the government has said it will help hospitals to pay off debts.

    “That has improved things, even though the situation should still be regarded as critical for the coming years,” Zachert said.

    Erbitux is Merck’s second best-selling prescription drug, bringing in sales of 855 million euros ($1.1 billion) in 2011 from treating bowel cancer and head and neck cancer. ($1 = 0.7785 euros)

    This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

    Print Friendly
    Be Sociable, Share!
    , , ,

    Leave a Reply

    You must be logged in to post a comment.